- Home
- UGI vs VRNA Comparison
UGI vs VRNA Comparison
Compare UGI & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGI
- VRNA
- Stock Information
- Founded
- UGI 1940
- VRNA 2005
- Country
- UGI United States
- VRNA United Kingdom
- Employees
- UGI N/A
- VRNA N/A
- Industry
- UGI Natural Gas Distribution
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- UGI Utilities
- VRNA Health Care
- Exchange
- UGI Nasdaq
- VRNA Nasdaq
- Market Cap
- UGI 7.7B
- VRNA 8.3B
- IPO Year
- UGI N/A
- VRNA 2017
- Fundamental
- Price
- UGI $36.33
- VRNA $104.90
- Analyst Decision
- UGI Buy
- VRNA Buy
- Analyst Count
- UGI 3
- VRNA 11
- Target Price
- UGI $31.33
- VRNA $114.10
- AVG Volume (30 Days)
- UGI 1.8M
- VRNA 7.2M
- Earning Date
- UGI 08-06-2025
- VRNA 08-07-2025
- Dividend Yield
- UGI 4.14%
- VRNA N/A
- EPS Growth
- UGI N/A
- VRNA N/A
- EPS
- UGI 2.46
- VRNA N/A
- Revenue
- UGI $7,318,000,000.00
- VRNA $118,535,000.00
- Revenue This Year
- UGI $6.56
- VRNA $893.95
- Revenue Next Year
- UGI $8.97
- VRNA $73.76
- P/E Ratio
- UGI $14.69
- VRNA N/A
- Revenue Growth
- UGI N/A
- VRNA N/A
- 52 Week Low
- UGI $23.09
- VRNA $18.51
- 52 Week High
- UGI $36.74
- VRNA $105.30
- Technical
- Relative Strength Index (RSI)
- UGI 56.94
- VRNA 70.69
- Support Level
- UGI $35.51
- VRNA $104.58
- Resistance Level
- UGI $36.59
- VRNA $104.91
- Average True Range (ATR)
- UGI 0.63
- VRNA 1.88
- MACD
- UGI 0.03
- VRNA 0.35
- Stochastic Oscillator
- UGI 86.87
- VRNA 97.86
About UGI UGI Corporation
UGI Corp is an American holding company that, through its subsidiaries, is involved in the transport and marketing of energy and related services. Its segments include AmeriGas Propane, UGI International, Midstream & Marketing, and Utilities. The AmeriGas Propane segment consists of the propane distribution business. The UGI International segment consists of LPG distribution businesses. The Midstream & Marketing segment consists of energy-related businesses. The Utilities segment consists of the regulated natural gas and electric distribution. The company derives a majority of its revenue from the UGI International segment.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.